Rockwell Medical, Inc. (DE) (RMTI) Stock: Buy, Sell, or Hold?
RMTI - Rockwell Medical, Inc. (DE) Common Stock
$8.65
0.08 (0.93%)
▲
5d:
+3.35%
30d:
+7.19%
90d:
+54.46%
WAIT
LOW Confidence
Analysis Updated: Oct 2, 2026 12:00 AM ET
Earnings: Nov 11, 2026
Get Alerted When RMTI Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: RMTI shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: RMTI shows conflicting indicators. Wait for confirmation before entering.
In-depth Analysis How we analyze
Valuation Analysis: RMTI is currently trading at $8.65, which is considered extended relative to its 30-day fair value range of $7.87 to $8.54. From a valuation perspective, the stock is trading at a discount (Forward PE: -42.2) compared to its historical average (17.3). At these levels, the market is pricing in 0% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, RMTI is in a strong uptrend. The price is approaching resistance at $8.90. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: RMTI scores 10/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $20.00 (+131.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, RMTI is in a strong uptrend. The price is approaching resistance at $8.90. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: RMTI scores 10/100 on our bottoming-setup gauge. Note this measures entry quality, not trend direction — a low score can mean the chart is extended after a strong run (don't chase) or still falling without stabilization; better entries typically come after a pullback toward the 20-day average. Wall Street analysts see significant upside, with an average price target of $20.00 (+131.2%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$7.87 -
$8.54
Company Quality Score
32/100
(SELL)
Volume Confirmation
HIGH
Confidence Score
33.3%
All Signals
- BEARISH: Price extended above range
- BEARISH: Weak technical setup (10/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 131.2% below Wall St target ($20.00)
- BULLISH: Market expects only 0% annual growth - appears undervalued
- WARNING: Composite score 32/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$7.87 -
$8.54
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$7.91
Resistance Level
$8.90
Current Trend
Strong Uptrend
Technical data as of
Oct 2, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-42.20
Wall Street Target
$20.00
(+131.2%)
Revenue Growth (YoY)
10.6%
Profit Margin
-7.3%
PE vs Historical
-42.2 vs 17.3
CHEAP
Share & Embed Analysis
Last updated: October 03, 2026 2:23 AM ET
Data refreshes hourly during market hours. Next update: 3:23 AM
Data refreshes hourly during market hours. Next update: 3:23 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RMTI showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$208 | 62 BUY |
|
ZTS
Zoetis Inc |
BUY
20 analysts |
$96 | 58 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$108 | 56 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 67 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 47 HOLD |
